DEA Greenlights Marijuana Study to Measure Pot’s Effect on PTSD

WASHINGTON TIMES — The U.S. Drug Enforcement Agency agreed for the first time ever this week to let researchers conduct clinical trials with marijuana to examine the potential benefits of using the plant to treat post-traumatic stress disorder.

A California-based nonprofit research group, the Multidisciplinary Approach to Psychedelic Studies (MAPS), announced on Thursday that the DEA will allow its scientists to conduct a double-blind, placebo-controlled study specifically designed to determine the potential benefits of medicinal marijuana with regards to treating PTSD.

“The DEA’s approval marks the first time a clinical trial intended to develop smoked botanical marijuana into a legal prescription drug has received full approval from U.S. regulatory agencies, including the DEA and the Food and Drug Administration,” MAPS said in a statement.

Share Button

Leave a Reply

Your email address will not be published. Required fields are marked *